Payment overview · 2025
General Payments
$621.03
42 reported records · 12 companies
Healthcare provider profile · identity verified
Kimberly R. Keith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1053361691
Verified facts
What the public records show
CMS Open Payments records show Kimberly R. Keith, M.D. received $621.03 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.04 | 24.3% | 18 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $134.97 | 21.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $90.31 | 14.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.31 | 11.2% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $49.64 | 8.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.24 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.06 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.90 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.88 | 2.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.75 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.20 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.73 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $621.03 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $105.68 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.31 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $89.29 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.31 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.75 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.75 | 12 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
263 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 588 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 95 |
| Losartan Potassium | Losartan Potassium | 342 | 94 |
| Famotidine | Famotidine | 309 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 92 |
| Lisinopril | Lisinopril | 281 | 77 |
| Ozempic | Semaglutide | 263 | 44 |
| Omeprazole | Omeprazole | 235 | 62 |
| Trazodone Hcl | Trazodone Hcl | 228 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 56 |
| Metformin Hcl | Metformin Hcl | 207 | 65 |
| Meloxicam | Meloxicam | 167 | 51 |
| Ezetimibe | Ezetimibe | 165 | 44 |
| Furosemide | Furosemide | 163 | 51 |
| Gabapentin | Gabapentin | 159 | 49 |
| Metformin Hcl Er | Metformin Hcl | 153 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 42 |
| Potassium Chloride | Potassium Chloride | 125 | 40 |
| Carvedilol | Carvedilol | 122 | 41 |
| Spironolactone | Spironolactone | 115 | 21 |
| Allopurinol | Allopurinol | 114 | 34 |
| Buspirone Hcl | Buspirone Hcl | 109 | 27 |
| Montelukast Sodium | Montelukast Sodium | 106 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 24 |
| Simvastatin | Simvastatin | 99 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 27 |
| Mounjaro | Tirzepatide | 96 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 35 |
| Tramadol Hcl | Tramadol Hcl | 91 | 41 |
| Celecoxib | Celecoxib | 89 | 26 |
| Eliquis | Apixaban | 88 | 17 |
| Alendronate Sodium | Alendronate Sodium | 83 | 27 |
| Glimepiride | Glimepiride | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 26 |
| Bupropion Xl | Bupropion Hcl | 73 | 20 |
| Farxiga | Dapagliflozin Propanediol | 73 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 19 |
| Synthroid | Levothyroxine Sodium | 70 | 20 |
| Sertraline Hcl | Sertraline Hcl | 69 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 19 |
| Mirtazapine | Mirtazapine | 64 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 19 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Atenolol | Atenolol | 56 | 15 |
| Donepezil Hcl | Donepezil Hcl | 55 | 18 |
| Fenofibrate | Fenofibrate | 53 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 43 |
| Mupirocin | Mupirocin | 52 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 13 |
| Clonazepam | Clonazepam | 49 | 14 |
| Cefdinir | Cefdinir | 47 | 37 |
| Meclizine Hcl | Meclizine Hcl | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Nystatin | Nystatin | 42 | 18 |
| Estradiol | Estradiol | 40 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Repaglinide | Repaglinide | 40 | 11 |
| Linzess | Linaclotide | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 18 |
| Lorazepam | Lorazepam | 37 | 18 |
| Valacyclovir | Valacyclovir Hcl | 37 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 13 |
| Fluconazole | Fluconazole | 36 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 13 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 12 |
| Torsemide | Torsemide | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 25 |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Prednisone | Prednisone | 19 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $621.03 · 42 records | Amgen Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, EVENITY, Enhertu, INJECTAFER, JARDIANCE, Kerendia, MCOT, OTEZLA, PREVNAR 20, PROLIA, QULIPTA, REPATHA, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error